Skip to main content

Holiday schedule

Quest Diagnostics Patient Service Centers will have modified hours during the holiday season.

  • Closing early at 12:00pm on December 31, 2025
  • Closed on January 1, 2026


Have a healthy, happy holiday!

Hide
Quest Diagnostics

NGS-Defined Measurable Residual Disease (MRD) After Initial Chemotherapy as a Prognostic Biomarker for Acute Myeloid Leukemia

 

NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia

Authors: Li Y, Solis-Ruiz J, Yang F, Long N, Tong CH, Lacbawan FL, Racke FK, Press RD

Blood Cancer J. 2023 Apr 24;13(1):59. doi: 10.1038/s41408-023-00833-7

Specialties: Oncology

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.